GA黄金甲

Recently, Nanjing Intellectual Property Office issued the "Decision on the Recognition of 2022 Nanjing Excellent Patent Award (Ning Zhi [2022] No. 25)", in which Nanjing Chia Tai Tianqing, a subsidiary of Sino Biopharm, won the Nanjing Excellent Patent Award for its invention patent "a method of preparing idarubicin hydrochloride".

The awarded patent involves the preparation method of Idarubicin Hydrochloride for Injection, a new product of Nanjing Chia Tai Tianqing, which has the advantages of less steps and low cost, while improving the quality of Idarubicin Hydrochloride. This award is also the first patent award obtained by Nanjing Chia Tai Tianqing in the research and development of Idarubicin, which plays a key role in the patent layout of Idarubicin.

Idarubicin is the fundamental treatment for AML (acute myeloid leukemia), a highly aggressive and rapidly progressive malignancy, recommended by both national and international guidelines. If left untreated, patients can develop infections or bleed to death within months. The IA(3+7) regimen of Idarubicin combined with Ara-C is the standard first-line regimen for AML treatment and plays a cornerstone role in reducing or eliminating residual lesions and prolonging survival. Among them, idarubicin is an antitumor antibiotic with a unique chemical structure and high drug lipid solubility and antitumor activity, which is an important component of this classical treatment regimen. Idarubicin has been clinically proven to be a guarantee of high remission rates and long survival when used in AML patients of different age groups and different risk strata, and the National Comprehensive Cancer Network (NCCN) clinical practice guidelines recommend idarubicin for the whole treatment of AML.

Idarubicin hydrochloride for injection (trademark name: Anbijian) developed by Sino Biopharm was approved in China in 2020, including two sizes of 5mg and 10mg, which is the first product of the same variety to pass the consistency evaluation in China.

At present, Nanjing Chia Tai Tianqing has applied for 5 domestic invention patents around idarubicin hydrochloride for injection, which brings more choices for patients and solves several key problems that plague the optimization of idarubicin production process, and promotes the development, industrial production and promotion of related products in China.

All along, Sino Biopharm has always attached great importance to the issue of patent and intellectual property protection. In 2021, the Group submitted 939 patent applications and obtained 290 patent invention authorizations. By 2021, the number of patents of the Group exceeded 1,000, reaching 1,229.

With more and more new products coming to market and the continuous development of pharmaceutical innovation, Sino Biopharm and its subsidiaries will continue to strengthen patent layout, give full play to the role of intellectual property rights in supporting and leading innovation development, build a solid "fortress" of intellectual property protection, and enhance the competitiveness of enterprises and products in the market.